These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14624190)

  • 1. Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone.
    Weiden PJ; Daniel DG; Simpson G; Romano SJ
    J Clin Psychopharmacol; 2003 Dec; 23(6):595-600. PubMed ID: 14624190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.
    Grootens KP; van Veelen NM; Peuskens J; Sabbe BG; Thys E; Buitelaar JK; Verkes RJ; Kahn RS
    Schizophr Bull; 2011 Mar; 37(2):352-61. PubMed ID: 19542525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
    Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
    Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study.
    Byerly MJ; Marcus RN; Tran QV; Eudicone JM; Whitehead R; Baker RA
    Schizophr Res; 2009 Feb; 107(2-3):218-22. PubMed ID: 19038534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.
    Lublin H; Haug HJ; Koponen H; Sigmundsson T; Kolb SA
    World J Biol Psychiatry; 2009; 10(4 Pt 3):710-8. PubMed ID: 18803070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine.
    Kinon BJ; Ahl J; Liu-Seifert H; Maguire GA
    Psychoneuroendocrinology; 2006 Jun; 31(5):577-88. PubMed ID: 16488084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone.
    Kim KS; Pae CU; Chae JH; Bahk WM; Jun TY; Kim DJ; Dickson RA
    J Clin Psychiatry; 2002 May; 63(5):408-13. PubMed ID: 12019665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of ziprasidone in the treatment of first-episode psychosis: an 8-week, open-label, multicenter trial.
    Zhao T; Park TW; Yang JC; Huang GB; Kim MG; Lee KH; Chung YC
    Int Clin Psychopharmacol; 2012 Jul; 27(4):184-90. PubMed ID: 22426471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A naturalistic, observational study of outpatients with schizophrenia: efficacy and safety results after 6 months. The International Schizophrenia Outpatient Health Outcomes study, IC-SOHO].
    István S; Agoston T; Tamás T; Zoltán J
    Neuropsychopharmacol Hung; 2007 Oct; 9(3):115-24. PubMed ID: 18399029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.
    Awad G; Hassan M; Loebel A; Hsu J; Pikalov A; Rajagopalan K
    BMC Psychiatry; 2014 Feb; 14():53. PubMed ID: 24559217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone.
    Rossi A; Vita A; Tiradritti P; Romeo F
    Int Clin Psychopharmacol; 2008 Jul; 23(4):216-22. PubMed ID: 18545060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients.
    Kinon BJ; Stauffer VL; McGuire HC; Kaiser CJ; Dickson RA; Kennedy JS
    J Am Med Dir Assoc; 2003; 4(4):189-94. PubMed ID: 12837139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of ziprasidone vs. olanzapine in naive first-episode schizophrenia: a 6-week, randomized, open-label, flexible-dose study.
    Li YM; Zhao JP; Ou JJ; Wu RR
    Pharmacopsychiatry; 2012 Jul; 45(5):177-81. PubMed ID: 22290206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum prolactin levels and the acute-phase efficacy in drug-naïve schizophrenia treated with ziprasidone and olanzapine (translated version).
    Wu XL; Wang JH; Hu SH; Tao J
    East Asian Arch Psychiatry; 2012 Mar; 22(1):7-11. PubMed ID: 22447799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
    Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
    N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
    Weiden PJ; Newcomer JW; Loebel AD; Yang R; Lebovitz HE
    Neuropsychopharmacology; 2008 Apr; 33(5):985-94. PubMed ID: 17637612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.
    Zink M; Kuwilsky A; Krumm B; Dressing H
    J Psychopharmacol; 2009 May; 23(3):305-14. PubMed ID: 18562423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.